Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multipl...
Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical ...
Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )
25 Sep 2019
PLEIADES: Daratumumab combinations for multiple myeloma
Dr Ajai Chari - Mount Sinai, New York City, USA
PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )
25 Sep 2019
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multipl...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multip...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Successful implementation of biosimilars through effective communication
Dr Pauline Leonard - The Whittington Hospital, London, UK
Successful implementation of biosimilars through effective communication ( Dr Pauline Leonard - The Whittington Hospital, London, UK )
25 Sep 2019
Practical considerations for introducing biosimilars
Simon Cheesman - University College Hospital, London, UK
Practical considerations for introducing biosimilars ( Simon Cheesman - University College Hospital, London, UK )
25 Sep 2019
How real-world data generation can assist biosimilar implementation
Simon Cheesman - University College Hospital, London, UK
How real-world data generation can assist biosimilar implementation ( Simon Cheesman - University College Hospital, London, UK )
25 Sep 2019
Regulatory principles for biosimilar medicines
Prof Paul Declerck - KU Leuven, Leuven, Belgium
Regulatory principles for biosimilar medicines ( Prof Paul Declerck - KU Leuven, Leuven, Belgium )
25 Sep 2019
Biologics utilisation and its efficiency through a hospital pharmacy centralised...
Jose Feio - University of Coimbra, Coimbra, Portugal
Biologics utilisation and its efficiency through a hospital pharmacy centralised management system ( Jose Feio - University of Coimbra, Coimbra, Portugal )
25 Sep 2019